Trial Profile
A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Edotecarin (Primary) ; Carmustine; Lomustine; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 27 Nov 2006 Status change
- 01 Sep 2006 The expected completion date for this trial is now 1 Mar 2006.
- 17 Sep 2005 New trial record.